FIA
TRVI icon

FNY Investment Advisers’s Trevi Therapeutics TRVI Stock Holding History

FNY Investment Advisers’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,986
Closed -$22K – 849
2022
Q2 		$22K Buy
+7,986
New +$19.6K 0.02% 315

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

FNY Investment Advisers's TRVI Position: Q3 2022 in Review

FNY Investment Advisers sold out of Trevi Therapeutics (TRVI) in Q3 2022, closing a stake of 7,986 shares — an estimated $22K sold.

FNY Investment Advisers first reported a position in TRVI in Q2 2022 and held it in 1 quarter. The position peaked at $22K in Q2 2022. 40 funds tracked by Wall St. Rank hold TRVI as of Q3 2022.

  • FNY Investment Advisers reported no remaining Trevi Therapeutics position as of Q3 2022 after selling out during the quarter.
  • FNY Investment Advisers sold 7,986 Trevi Therapeutics shares in Q3 2022, an estimated $22K.
  • FNY Investment Advisers first reported a position in Trevi Therapeutics in Q2 2022 and held it in 1 quarter.
  • FNY Investment Advisers's Trevi Therapeutics position peaked at $22K in Q2 2022.
  • 40 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2022.

Based on FNY Investment Advisers's 13F filing for Q3 2022, filed 19 Oct 2022.